Results from CONTESSA 2: A Multinational, Multicenter, Phase 2 Study of Tesetaxel (T) Plus a Reduced Dose of Capecitabine (C) in Patients (pts) with Hormone Receptor + (HR+), HER2- Metastatic Breast Cancer (MBC) Not Previously Treated with a Taxane.